Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00186095
NCT00186095WithdrawnNot Applicable

Mixed Chimeric Transplantation for Primary Amyloidosis

Stanford University0 sitesStarted: December 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Primary Endpoint
Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
— to 60 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •primary amyloidosis
  • •adequate organ function
  • •matched sibling donor

Exclusion Criteria

  • •evidence of multiple myeloma
  • •HIV positive

Outcomes

Primary Outcomes

Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcomes

  • Toxicity of therapy
  • Changes in marrow and serum abnormalities
  • Improvement in end-organ function.

Investigators

Sponsor Class
Other

Similar Trials

Completed
Phase 2
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple MyelomaBlood CancerMultiple Myeloma
NCT00185614Wen-Kai Weng63
Completed
Not Applicable
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple MyelomaMultiple Myeloma
NCT00185653Stanford University40
Unknown
Phase 2
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)Multiple Myeloma
NCT00702247Azienda Ospedaliera San Giovanni Battista
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell LymphomaMycosesSezary SyndromeLymphoma, T-Cell, CutaneousBone Marrow Transplant FailureLymphoma, Non-HodgkinCutaneous T-cell Lymphoma
NCT00896493Stanford University38
Completed
Not Applicable
Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell TransplantationAmyloidosis
NCT01606280Mayo Clinic400